Drug intelligence / Profile preview

Multivalent pneumococcal conjugate formulation 2

Development stage
Unknown
Lead developer
Sanofi
Modality
Vaccines & Immunotherapeutics
Administration
Intramuscular
01

Overview

This item is described as 'multivalent pneumococcal conjugate formulation 2', identified as the freeze-dried powder component of a two-part ('1+1' combination mode) pneumococcal conjugate vaccine system. It contains pneumococcal conjugates prepared from serotypes 8, 10A, 11A, 15B, 22F, 24F, 33F, and 35B, utilizing tetanus toxoid as carrier proteins. This formulation is designed to either supplement existing pneumococcal conjugate vaccines (like 10-valent or 13-valent ones) to broaden coverage or combine with a liquid component (containing 15 serotypes) to create a broader-spectrum vaccine (potentially covering 23 serotypes in total).

Other names
Freeze-dried pneumococcal vaccine component
02

Targets

CPS (Streptococcus pneumoniae capsular polysaccharide)

Beyond the preview

Go deeper on Multivalent pneumococcal conjugate formulation 2.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Multivalent pneumococcal conjugate formulation 2.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call